State Street Corp Buys 1,182,181 Shares of Replimune Group, Inc. (NASDAQ:REPL)

State Street Corp raised its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 102.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,340,042 shares of the company's stock after acquiring an additional 1,182,181 shares during the quarter. State Street Corp owned approximately 3.42% of Replimune Group worth $25,647,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in REPL. Millennium Management LLC boosted its position in shares of Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock valued at $28,062,000 after purchasing an additional 2,656,173 shares in the last quarter. Braidwell LP lifted its position in Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company's stock valued at $33,656,000 after buying an additional 2,057,460 shares during the period. Baker BROS. Advisors LP boosted its holdings in shares of Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock valued at $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Parkman Healthcare Partners LLC grew its position in shares of Replimune Group by 45.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company's stock worth $8,371,000 after buying an additional 238,747 shares during the period. Finally, Arizona PSPRS Trust bought a new position in shares of Replimune Group in the 3rd quarter worth about $834,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Insider Activity

In other news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares of the company's stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company's stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 24th. HC Wainwright restated a "buy" rating and issued a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. BMO Capital Markets raised their price objective on Replimune Group from $14.00 to $18.00 and gave the company an "outperform" rating in a research report on Friday, November 22nd. Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 target price on the stock. Finally, Roth Capital upgraded Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $17.29.

Replimune Group Stock Down 1.2 %

REPL traded down $0.15 during trading on Monday, hitting $12.34. 709,186 shares of the company's stock traded hands, compared to its average volume of 1,051,318. The stock has a market capitalization of $844.27 million, a price-to-earnings ratio of -4.05 and a beta of 1.26. The company's 50 day simple moving average is $12.28 and its two-hundred day simple moving average is $10.80. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. Analysts predict that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.